PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components

Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline BRCA1/2 mutations, but as evidence and approvals for their use in a wider range of patients grow, the question of how best to identify patients who would benefit from PARPi becomes...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan Coyne, Geraldine, Karlovich, Chris, Wilsker, Deborah, Voth, Andrea Regier, Parchment, Ralph E, Chen, Alice P, Doroshow, James H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885121/
https://www.ncbi.nlm.nih.gov/pubmed/35237050
http://dx.doi.org/10.2147/OTT.S278092
Descripción
Sumario:Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline BRCA1/2 mutations, but as evidence and approvals for their use in a wider range of patients grow, the question of how best to identify patients who would benefit from PARPi becomes ever more complex. Here, we discuss the development and current state of approved selection testing for PARPi therapy and the ongoing efforts to define a broader range of homologous recombination repair deficiencies that are susceptible to PARP inhibition.

Ejemplares similares